TCG Crossover — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Ollin Biosciences, Inc.May 2026SEC filingmedium confidence
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
BiotechAustin, US
Alaa Halawa(Director)Jason Ehrlich(Executive Officer, Director)Jason Coloma(Director)
BoardTravis Murdoch(Director)Fred Cohen(Director)
Board seatCariad Chester· per SEC Form D · $330M raise · filed Jun 2026
Co-investorsMonograph Capital PartnersARCH Venture PartnersMC Healthcare Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.